Abbott Laboratories (ABT)

A portfolio of dividend payers with decade-long track records is outrunning the AI-heavy growth indexes.

Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.

A recent acquisition is already bearing fruit.

Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares.

Why is the Dow holding up while the Nasdaq sinks? Healthcare gains are offsetting the semiconductor carnage.

Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara

Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ...

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Don't sleep on these medical device leaders.

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

The Schwab U.S. Dividend Equity ETF is anything but boring.

Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.

All three ETFs complement each other well in a portfolio.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.